Manolis Abatzis-Papadopoulos

Mr. Manolis Abatzis-Papadopoulos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Orthopaedics & Traumatology: Surgery & Research
Verified
Journal Article
Closed access
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KTKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
SNSpyridon Nikas
Spyridon Nikas
IPIoakeim Papoutsis
Ioakeim Papoutsis
OKOlympia Kostopoulou
Olympia Kostopoulou
NSNikolaos Saratzis
Nikolaos Saratzis

8 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
SNSpyridon Nikas
Spyridon Nikas
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KSKyriakos Stavridis
Kyriakos Stavridis
NSNikolaos Saratzis
Nikolaos Saratzis
Background: Prospective single and multicenter studies have shown improved outcomes of patients who underwent carotid artery stenting with the novel CGuard dual-layer mesh stent at 1 year. Objectives: The aim of this study is to conduct a systematic review and meta-analysis of all published studies to assess 1-year efficacy and outcomes of CGuard in patients with carotid stenting. Methods: A systematic search was performed. All studies enrolling at least 20 patients were included in our analysis. The primary endpoints were death (all-cause, cardiovascular and ipsilateral stroke-related death) and stroke rate at 1 year. The secondary endpoint was in-stent restenosis at 1 year. Results: The final analysis included 1709 patients. The one-year all-cause mortality rate was 2.97% (39/1699, 95% CI: 1.26–6.86%, I2 = 67%, t2 = 0.3442, p < 0.01), cardiovascular-related death was 0.92% (10/1616, 95% CI: 0.35–2.39%, I2 = 34%, t2 = 0.2302, p = 0.18), and ipsilateral stroke-related death was 0.3% (1/1649, 95% CI: 0.1–0.87%, I2 = 0%, t2 = 0, p = 0.69). The one-year ipsilateral stroke rate was 1.21% (16/1649, 95% CI: 0.58–2.5%, I2 = 28%, t2 = 0.1433, p = 0.23), transient ischemic attacks (TIAs) rate was 1.78% (19/1149, 95% CI: 1.11–2.84%, I2 = 0%, t2 = 0, p = 0.69), and total composite 1-year stroke/TIA rate was 2.97% (32/1149, 95% CI: 1.84–4.77%, I2 = 0%, t2 = 0, p = 0.41). The in-stent restenosis rate at 1 year was 1.06% (13/1653, 95% CI: 0.48–2.34%, I2 = 28%, t2 = 0.2308, p = 0.22). Conclusions: This meta-analysis shows that CAS with CGuard is safe with minimal neurological adverse events and in-stent restenosis rate at 1 year.

17 July 2023 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KTKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
SNSpyridon Nikas
Spyridon Nikas
KSKaterina Sidiropoulou
Katerina Sidiropoulou
CAChristina Alexou
Christina Alexou
NSNikolaos Saratzis
Nikolaos Saratzis

24 December 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KSKyriakos Stavridis
Kyriakos Stavridis
DKDimitrios G. Karamanos
Dimitrios G. Karamanos
NSNikolaos Saratzis
Nikolaos Saratzis
Background and Objectives: Endovascular technologies have significantly improved the outcome of patients with critical limb ischemia (CLI). Drug eluting stents (DES) have documented their efficacy against percutaneous transluminal angioplasty (PTA) and bare metal stents (BMS) in infrapopliteal arterial occlusive disease. However, late in-stent neoatherosclerosis may lead to vascular lumen loss and eventually thrombosis. Polymer free DES constitute a new technology aiming to improve long term patency which their action is still under investigation. The purpose of this study is to report the mechanism of action and to provide a literature review of a novel polymer free amphilimus eluting stent (Cre8, Alvimedica, Instabul, Turkey) in infrapopliteal arterial disease. Methods: Publications listed in electronic databases, European Union Drug Regulating Authorities Clinical Trials Database, as well as scientific programmes of recent interventional vascular conferences were searched. Three studies were included. We analyzed primary and secondary patency, major amputation rate, freedom from CD-TLR, and mortality. Results: Cre8 was implanted in 79 patients with CLI. Most of the patients (n = 65) were Rutherford class 5–6 (82.3%), and diabetes mellitus (DM) was present in 66 patients (83.5%). Mean primary patency was 82.5% at 12 months. Mean lesion stented length was 20 mm and 35 mm in two studies. Mean limb salvage was 91.3% at 12 months. Freedom from CD-TLR was reported in two out of the three studies and was 96% and 83.8%. Mortality was 15% and 23.8% in the same studies, whilst it was not reported in one study. Conclusion: Stenting of infrapopliteal arteries with Cre8 is safe and feasible in patients with CLI and diabetes. All studies have shown very good primary patency and freedom from CD-TLR at 12 and 24 months. Larger observational prospective studies and randomized trials are necessary to establish long term effectiveness and clinical outcomes using the non-polymer Cre8 DES.

23 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
SNSpyridon Nikas
Spyridon Nikas
CAChristina Antza
Christina Antza
CAChristina Alexou
Christina Alexou
NSNikolaos Saratzis
Nikolaos Saratzis
Background/Objectives: Aortic stiffness is a strong independent factor in cardiovascular outcomes. The method of choice for evaluating aortic stiffness is the measurement of aortic pulse wave velocity (PWV). Endovascular aortic repair (EVAR) increases aortic rigidity and thus aortic stiffness. The aim of this study is to investigate the correlation between endograft length and post-operative increases in PWV in patients with abdominal aortic aneurysms (AAAs) subjected to EVAR. Methods: A prospective observational study enrolling 107 patients from February to December 2025 was conducted. Patient demographics and comorbidities were recorded. The length of the endografts was calculated by studying computed tomography angiograms (CTAs) and digital subtraction angiographies (DSAs) of the patients. PWV was measured pre-operatively and post-operatively during the first 24 h after EVAR, and the difference in PWV (dPWV) was calculated. Results: The mean age of the patients was 72 ± 7.5 years, and 93.5% of them were males. The mean transverse AAA diameter was 5.7 ± 1.1 mm, and the mean endograft length was 169.7 ± 26.9 mm. An extension to the external iliac artery was deployed in 10 patients (9.3%). A strong positive correlation was observed between dPWV and endograft length, indicating that each additional 1 mm in graft length corresponded to a 0.541% increase in dPWV. Patients with an extension to external iliac arteries exhibited a significantly higher mean dPWV (9.95 ± 2.08% vs. 27.12% ± 12.15%, t = −4.463, p = 0.002). No statistically significant differences in dPWV between the different endograft types were found (p = 0.74). Conclusions: Endograft length is strongly related to PWV elevation during the immediate post-operative time after EVAR, especially when the endograft is extended to the external iliac arteries.

11 June 2023 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
IPIoakeim Papoutsis
Ioakeim Papoutsis
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KSKyriakos Stavridis
Kyriakos Stavridis
NSNikolaos Saratzis
Nikolaos Saratzis
Objective: The purpose of this retrospective cohort study is to report outcomes of endovascular aortic repair (EVAR) with the novel endograft, Ankura (Lifetech Scientific, Shenzen, China). Methods: We identified all patients who underwent elective EVAR with Ankura stent graft in a tertiary unit from January 2015 to November 2021. Patients with ruptured infrarenal and juxtarenal aortic aneurysms were excluded from the study. All patients were anatomically suitable according to the instructions for use (IFU). Follow-up (FU) included computed tomography angiography (CTA) at 1 month, 12 months, and yearly thereafter if endoleak (EL) was not present. Primary outcomes included technical success (primary and secondary) and 30-day overall mortality and morbidity. Secondary outcomes included late overall and aneurysm-related mortality as well as influence of suprarenal fixation of the endograft on renal function at 12 months using eGFR (CKI-EPI formula). Results: The Ankura endograft was successfully implanted in 116 patients (mean age=71.1 years, 96.5% male). Mean aneurysm diameter was 62.3 mm. Median FU was 34 months (2-72 months). Primary and secondary technical success were 95.7% and 100%, respectively. Overall type I EL was 5% (2 proximal, 3 distal) and type II EL was 13%. Thirty days mortality and morbidity were 0% and 5.2%, respectively. All-cause mortality during FU was 13.9% (n=16); aneurysm-related mortality was 2.6% (n=3). Limb endograft patency was 100%. Freedom from reintervention was 98.2% at 2 years, and 97.4% at 4 and 6 years respectively. There was a statistically significant difference between preoperative (73.69 mL/min/1.73 m 2 ) and postoperative (66.66 mL/min/1.73 m 2 ) eGFR at 12 months (p<0.001). Conclusion: Ankura endograft has demonstrated an efficacious durability with low aneurysm-related mortality and high iliac limb patency rate. Elective EVAR is associated with significant decline in renal function at 12 months in our study. Larger series studies are necessary to evaluate long-term safety and efficacy of Ankura endograft. Clinical Impact: Ankura stent graft is a novel PTFE endograft with suprarenal fixation for infrarenal aneurysm repair. This retrospective cohort study of 116 patients provide a first “picture” of Ankura safety and efficacy in a European tertiary vascular center. High technical success rate, low aneurysm related mortality and high limb patency rate are the main findings of the study with a negative impact of suprarenal fixation on kidney function during follow up.